These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7866205)

  • 21. Betaseron for multiple sclerosis. Implications for therapeutics.
    Rudick RA
    Arch Neurol; 1994 Feb; 51(2):125-8. PubMed ID: 8304836
    [No Abstract]   [Full Text] [Related]  

  • 22. Development of ulcerative colitis in a patient with multiple sclerosis following treatment with interferon beta 1a.
    Schott E; Paul F; Wuerfel JT; Zipp F; Rudolph B; Wiedenmann B; Baumgart DC
    World J Gastroenterol; 2007 Jul; 13(26):3638-40. PubMed ID: 17659718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacogenomics of interferon beta and glatiramer acetate response: a review of the literature.
    Mahurkar S; Suppiah V; O'Doherty C
    Autoimmun Rev; 2014 Feb; 13(2):178-86. PubMed ID: 24189284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimizing immunomodulatory therapy for MS patients: an integrated management model.
    Jeffery D; Bashir K; Buchwald L; Coyle P; Freedman M; Markowitz C; Rammohan K; Reder T; Sharief M; Wolinsky J
    J Neurol Sci; 2002 Sep; 201(1-2):89-90. PubMed ID: 12163200
    [No Abstract]   [Full Text] [Related]  

  • 25. Interferon beta treatment for multiple sclerosis.
    Goodin DS
    Lancet; 1999 Feb; 353(9151):495-6; author reply 497-8. PubMed ID: 9989741
    [No Abstract]   [Full Text] [Related]  

  • 26. Interferon beta treatment for multiple sclerosis.
    Galazka A
    Lancet; 1999 Feb; 353(9151):495; author reply 497-8. PubMed ID: 9989740
    [No Abstract]   [Full Text] [Related]  

  • 27. Interferon beta treatment for multiple sclerosis.
    O'Connor P
    Lancet; 1999 Feb; 353(9151):496; author reply 497-8. PubMed ID: 9989742
    [No Abstract]   [Full Text] [Related]  

  • 28. [Problems and prospects of beta-interferon and copaxone++ application in the treatment of multiple sclerosis].
    Gusev EI; Boĭko AN; Pozer Ch
    Zh Nevrol Psikhiatr Im S S Korsakova; 1999; 99(4):33-6. PubMed ID: 10319395
    [No Abstract]   [Full Text] [Related]  

  • 29. [Side-effects of the treatment with disease modifying drugs in patients with multiple sclerosis: an analysis of register data in the Yaroslavl region].
    Spirin NN; Kasatkin DS; Stepanov IO; Shipova EG; Baranova NS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(8):27-33. PubMed ID: 23096035
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment.
    Lucchinetti C; Brück W; Noseworthy J
    Curr Opin Neurol; 2001 Jun; 14(3):259-69. PubMed ID: 11371747
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Natalizumab for relapsing remitting multiple sclerosis.
    Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I
    Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pathogenesis and treatment of multiple sclerosis (state of the art in 2000)].
    Zavalishin IA; Zhuchenko TD; Peresedova AV
    Vestn Ross Akad Med Nauk; 2001; (7):18-22. PubMed ID: 11523422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Needed in MS: evidence, not EVIDENCE.
    Kieburtz K; McDermott M
    Neurology; 2002 Nov; 59(10):1482-3. PubMed ID: 12451186
    [No Abstract]   [Full Text] [Related]  

  • 34. Multiple sclerosis: monotherapy rules.
    Hauser SL; Josephson SA; Johnston SC
    Ann Neurol; 2013 Mar; 73(3):A5-6. PubMed ID: 23596013
    [No Abstract]   [Full Text] [Related]  

  • 35. Workshop on primary progressive multiple sclerosis: meeting summary.
    Montalban X; Thompson AJ
    Mult Scler; 2002 Apr; 8(2):177-8. PubMed ID: 11990876
    [No Abstract]   [Full Text] [Related]  

  • 36. Randomized controlled trials to assess therapies for multiple sclerosis.
    Wingerchuk DM; Noseworthy JH
    Neurology; 2002 Apr; 58(8 Suppl 4):S40-8. PubMed ID: 11971125
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of interferon beta 1b for multiple sclerosis. Importance of relapses must not be underestimated.
    Cardy P
    BMJ; 1996 Nov; 313(7067):1263. PubMed ID: 8939142
    [No Abstract]   [Full Text] [Related]  

  • 38. Interferon beta in multiple sclerosis.
    Richards RG
    BMJ; 1996 Nov; 313(7066):1159. PubMed ID: 8916730
    [No Abstract]   [Full Text] [Related]  

  • 39. [Interferon-beta 1a in therapy of relapsing-remitting multiple sclerosis].
    Hartung HP; Hohlfeld R
    Nervenarzt; 1997 Jun; 68(6):525-7. PubMed ID: 9312688
    [No Abstract]   [Full Text] [Related]  

  • 40. Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
    Hernandez L; Guo S; Kinter E; Fay M
    J Med Econ; 2016 Jul; 19(7):684-95. PubMed ID: 26947984
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.